Biomarkers – Products

Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis.

This whitepaper explores the translational and clinical applications of IMC to develop biomarkers and future treatment strategies in neuro-oncology and neurodegenerative studies.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced updates on its oncology assay portfolio and regulatory milestones, ahead of its presence at the AMP 2024 meeting.

This application note showcases how this robust, highly multiplexed platform supports novel biomarker discovery in drug development and aids in developing diagnostics for a wide range of critical diseases.

This application note examines an advanced proteomics platform designed to provide high precision across thousands of proteins, enabling reliable results even in large-scale and longitudinal studies.

Thermo Fisher Scientific has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with Servier Pharmaceuticals.

MOBILion Systems, Inc., announced a next-generation approach for complex sample analysis poised to disrupt the mass spectrometry industry as it delivers unparalleled speed, sensitivity, specificity and quantitative accuracy.

Diagnostic company SphingoTec GmbH (“SphingoTec”) announced a new partnership with Beckman Coulter Diagnostics Inc. (“Beckman Coulter”).

Owlstone Medical (“Owlstone”), announced it has entered into a Research Collaboration Agreement with the FDA’s Center for Devices and Radiological Health (“CDRH”) - Office of Science and Engineering Laboratories (OSEL).

Azenta, Inc. has announced its participation in the FinnGen project, a large-scale research initiative at the forefront of personalized medicine in Finland.